A Phase I Study of the Immune Response to Herpes Simplex Virus Type 1 (HSV-1) and General Immune Health in Subjects Infected With HSV-1
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2019
Price : $35 *
At a glance
- Drugs Squaric acid dibutylester (Primary)
- Indications Herpes simplex virus type 1 infections
- Focus Pharmacodynamics; Pharmacogenomic
- Sponsors Squarex
- 14 Feb 2019 According to a Squarex media release, clinical data from the study has been published in the peer-reviewed journal Immunity, Inflammation and Disease.
- 14 Feb 2019 Results presented in a Squarex media release.
- 17 Sep 2018 New trial record